Our analysis revealed that tumours treated with PI3K/mTORi and PI3K/mTORi+PD‐1i exhibited significantly higher levels of tumour‐infiltrating activated CD8+ T cells (% of activated CD8+ T cells/mm2 of tumour area) compared to those treated with vehicle or PD‐1i alone (Figure S3E). This evidence concerns the gene CD8A and neoplasm.